Lead Product(s) : Rostaporfin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Details : REM-001 (rostaporfin) is a second-generation photodynamic therapy (PDT) photosensitizer agent in development for the treatment of cutaneous metastatic breast cancer.
Brand Name : REM-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2024
Lead Product(s) : Rostaporfin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?